Oppenheimer & Co. Inc. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Oppenheimer & Co. Inc. reduced its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 66.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,480 shares of the company's stock after selling 22,648 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in CRISPR Therapeutics were worth $452,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Baker BROS. Advisors LP raised its stake in CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock valued at $39,608,000 after purchasing an additional 743,075 shares in the last quarter. State Street Corp lifted its holdings in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after acquiring an additional 599,304 shares during the period. Van ECK Associates Corp boosted its holdings in shares of CRISPR Therapeutics by 5,269.3% in the 4th quarter. Van ECK Associates Corp now owns 83,010 shares of the company's stock valued at $3,267,000 after purchasing an additional 81,464 shares in the last quarter. Finally, KBC Group NV boosted its stake in CRISPR Therapeutics by 2,047.4% in the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after buying an additional 57,696 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CRSP shares. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Barclays increased their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Needham & Company LLC reissued a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. Finally, Morgan Stanley lifted their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded down $0.54 during trading hours on Monday, hitting $45.00. The stock had a trading volume of 362,676 shares, compared to its average volume of 2,218,643. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of -10.46 and a beta of 1.77. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $79.33. The company has a 50 day simple moving average of $42.79 and a two-hundred day simple moving average of $45.74.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Buying and Selling

In other news, Director John Greene acquired 7,000 shares of the stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares in the company, valued at approximately $313,950. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.